Y. Perel et al., DIAGNOSIS AND TREATMENT OF PHEOCHROMOCYTO MA IN CHILDHOOD - A RETROSPECTIVE STUDY CONDUCTED IN FRANCE, Annales de pediatrie, 45(4), 1998, pp. 201-209
In children, pheochromocytoma and paraganglioma are exceedingly rare a
nd may exhibit a number of specific features including familial aggreg
ation, a multifocal distribution, and a malignant behavior. A retrospe
ctive study of 24 cases of pheochromocytoma and paraganglioma managed
in French Society for Pediatric Oncology centers was conducted with sp
ecial attention to long-term outcomes. Median age at diagnosis was 12.
5 years, and the most common presenting symptom was arterial hypertens
ion. Catecholamine assays and modern imaging methods (MIBG scintigraph
y, ultrasonography, computed tomography, and magnetic resonance imagin
g) established the diagnosis and determined the location of the tumor,
obviating the need for more invasive investigations. As many as six o
f the 24 patients had synchronous tumors in both adrenal glands, and e
ight had a familial form. There were no deaths during surgery or the i
mmediate postsurgical period. Median follow-up was 5.2 years. One pati
ent died, from progression of the tumor. Fourteen patients were still
in complete remission at last follow-up, whereas ten had had a recurre
nce and six of these ten had evidence of malignant behavior (local inv
asion or metastatic spread). In half the patients, repeated or extensi
ve surgery was responsible for sequelae, of which the most common were
endocrine deficiencies. Factors associated with a higher risk of recu
rrence or malignancy included location outside the adrenal gland, subs
tantial locoregional spread at the time of the first surgical procedur
e, and large tumor size. Early diagnosis (especially in patients with
a family history or a predisposing disease) and accurate assessment of
tumor spread before and after surgery add greatly to the likelihood o
f complete surgical excision, which is the only curative therapy, incl
uding during recurrences. Patients in remission should receive long-te
rm follow-up (catecholamines, MIBG scintigraphy) on a yearly basis.